CRSP
Price
$55.08
Change
-$1.63 (-2.87%)
Updated
Dec 26 closing price
Capitalization
5.25B
52 days until earnings call
Intraday BUY SELL Signals
NTLA
Price
$9.44
Change
-$0.15 (-1.56%)
Updated
Dec 26 closing price
Capitalization
1.09B
54 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CRSP vs NTLA

Header iconCRSP vs NTLA Comparison
Open Charts CRSP vs NTLABanner chart's image
CRISPR Therapeutics AG
Price$55.08
Change-$1.63 (-2.87%)
Volume$1.41M
Capitalization5.25B
Intellia Therapeutics
Price$9.44
Change-$0.15 (-1.56%)
Volume$1.84M
Capitalization1.09B
CRSP vs NTLA Comparison Chart in %
View a ticker or compare two or three
VS
CRSP vs. NTLA commentary
Dec 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a Buy and NTLA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 27, 2025
Stock price -- (CRSP: $55.08 vs. NTLA: $9.44)
Brand notoriety: CRSP and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRSP: 66% vs. NTLA: 25%
Market capitalization -- CRSP: $5.25B vs. NTLA: $1.09B
CRSP [@Biotechnology] is valued at $5.25B. NTLA’s [@Biotechnology] market capitalization is $1.09B. The market cap for tickers in the [@Biotechnology] industry ranges from $117.45B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRSP’s FA Score shows that 0 FA rating(s) are green whileNTLA’s FA Score has 1 green FA rating(s).

  • CRSP’s FA Score: 0 green, 5 red.
  • NTLA’s FA Score: 1 green, 4 red.
According to our system of comparison, NTLA is a better buy in the long-term than CRSP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRSP’s TA Score shows that 4 TA indicator(s) are bullish while NTLA’s TA Score has 3 bullish TA indicator(s).

  • CRSP’s TA Score: 4 bullish, 4 bearish.
  • NTLA’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, CRSP is a better buy in the short-term than NTLA.

Price Growth

CRSP (@Biotechnology) experienced а -1.40% price change this week, while NTLA (@Biotechnology) price change was +2.28% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.36%. For the same industry, the average monthly price growth was +0.27%, and the average quarterly price growth was +54.56%.

Reported Earning Dates

CRSP is expected to report earnings on Feb 17, 2026.

NTLA is expected to report earnings on Feb 19, 2026.

Industries' Descriptions

@Biotechnology (+0.36% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($5.25B) has a higher market cap than NTLA($1.09B). CRSP YTD gains are higher at: 39.939 vs. NTLA (-19.039). NTLA has higher annual earnings (EBITDA): -466.25M vs. CRSP (-555.73M). CRSP has more cash in the bank: 1.92B vs. NTLA (511M). NTLA has less debt than CRSP: NTLA (98M) vs CRSP (211M). NTLA has higher revenues than CRSP: NTLA (57.5M) vs CRSP (35M).
CRSPNTLACRSP / NTLA
Capitalization5.25B1.09B480%
EBITDA-555.73M-466.25M119%
Gain YTD39.939-19.039-210%
P/E RatioN/AN/A-
Revenue35M57.5M61%
Total Cash1.92B511M375%
Total Debt211M98M215%
FUNDAMENTALS RATINGS
CRSP vs NTLA: Fundamental Ratings
CRSP
NTLA
OUTLOOK RATING
1..100
108
VALUATION
overvalued / fair valued / undervalued
1..100
72
Overvalued
21
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9697
PRICE GROWTH RATING
1..100
4662
P/E GROWTH RATING
1..100
78100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (21) in the Biotechnology industry is somewhat better than the same rating for CRSP (72). This means that NTLA’s stock grew somewhat faster than CRSP’s over the last 12 months.

NTLA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CRSP (100). This means that NTLA’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's SMR Rating (96) in the Biotechnology industry is in the same range as NTLA (97). This means that CRSP’s stock grew similarly to NTLA’s over the last 12 months.

CRSP's Price Growth Rating (46) in the Biotechnology industry is in the same range as NTLA (62). This means that CRSP’s stock grew similarly to NTLA’s over the last 12 months.

CRSP's P/E Growth Rating (78) in the Biotechnology industry is in the same range as NTLA (100). This means that CRSP’s stock grew similarly to NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRSPNTLA
RSI
ODDS (%)
Bullish Trend 4 days ago
70%
Bullish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
86%
MACD
ODDS (%)
Bullish Trend 2 days ago
62%
Bullish Trend 2 days ago
77%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 6 days ago
78%
Bullish Trend 6 days ago
76%
Declines
ODDS (%)
Bearish Trend 11 days ago
84%
Bearish Trend 11 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
CRSP
Daily Signal:
Gain/Loss:
NTLA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EMRSX20.980.16
+0.77%
JPMorgan Emerging Mkts Rsrch Enh Eq R6
NEMCX25.680.19
+0.75%
Neuberger Emerg Mkts Eq C
JNBZX10.600.01
+0.09%
JPMorgan Income Builder R6
PLIEX32.460.01
+0.03%
Plumb Equity Institutional
FIKBX39.85N/A
N/A
Fidelity Advisor Financials Z

CRSP and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRSP has been closely correlated with BEAM. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRSP jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRSP
1D Price
Change %
CRSP100%
-2.87%
BEAM - CRSP
71%
Closely correlated
-0.57%
RXRX - CRSP
67%
Closely correlated
-3.41%
ABSI - CRSP
60%
Loosely correlated
+0.28%
NTLA - CRSP
60%
Loosely correlated
-1.56%
PRME - CRSP
60%
Loosely correlated
-1.96%
More

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with VCYT. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
-1.56%
VCYT - NTLA
69%
Closely correlated
-0.65%
BEAM - NTLA
61%
Loosely correlated
-0.57%
CRSP - NTLA
60%
Loosely correlated
-2.87%
AXON - NTLA
55%
Loosely correlated
-1.24%
CDXS - NTLA
50%
Loosely correlated
-2.98%
More